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impaired fasting glucose) are increasingly contributing to the global burden of disease. Despite the
continued introduction of hypoglycemic drugs, intervention in diabetes and its related complica-
tions remains a major global medical problem. Traditional Chinese medicine offers a number of
potential candidates for developing hypoglycemic drugs. Berberine (BER), an isoquinoline alkaloid
extract, has been commonly used as an oral drug to treat gastroenteritis and diarrhea for more than
1400 years. Although the antidiabetic effect of berberine has been noted in diabetic patients and
demonstrated diabetic animal models in the last decade, its use is not yet accepted in the general
medical community, for two reasons: its mechanism of action remains to be determined, and its
bioavailability is low. Therefore, characterization of its mechanism of action and enhancement of
its bioavailability are most important and the subject of current investigations. Recent studies have
also revealed beneﬁcial effects of berberine on diabetic complications. In this review the antidiabetic
mechanism of action of berberine, its effect on diabetic complications, and efforts to improve its
bioavailability are summarized. These studies may lead to its wider use for the treatment of type 2
diabetes mellitus and its complications.
& 2012 Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical
Association. Production and hosting by Elsevier B.V. All rights reserved.edica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association. Production and
rved.




Ming Zhang, Li Chen3801. Introduction
Diabetes is one of the earliest diseases to be recognized, and
can be traced to 400 BCE where it was described by Indian
physicians. The term ‘‘diabetes’’ or ‘‘to pass through’’ was ﬁrst
used in 230 CE by the Greek Appollonius of Memphis1.
Effective treatments were not available until the early part of
the 20th century, when the Canadians Frederick Banting and
Charles Best developed insulin in 1921 and 19221.
According to statistics, world-wide there were 285 million
people with type 2 diabetes, making up about 90% of diabetes
cases in 2010. In China, the prevalence of diabetes is also high
and is increasing; the incidence of diabetes in 2010 was
estimated at 92.4 million adults with 43.1 million rural and
49.3 million urban patients. Nearly one third of the diabetic
patients in the world live in China, the most of any country2.
This high and increasing incidence of diabetes is believed
primarily to be due to global population aging, a decrease in
exercise, smoking, elevated cholesterol levels, high blood
pressure, and increasing rates of obesity.
In the majority of patients with type 2 diabetes (T2D), oral
antidiabetic drug (OAD) treatment is the ﬁrst-line treatment
after lifestyle measures fail. The most commonly prescribed
blood-glucose lowering agents, metformin, sulfonylurea and
thiazolidinedione, may temporarily improve blood glucose
control. However, despite the continuing introduction of
hypoglycemic drugs, intervention in diabetes and its related
complications remains a major global medical problem.
Traditional Chinese medicine has the potential to contribute
new candidates for the development of hypoglycemic drugs.
Berberine (BER) is the major active component of Rhizoma
Coptidis which can be prepared from rhizomes of several herbs
including Coptis chinensis French, Coptis deltoidea and Coptis
teetoides. Rhizoma Coptidis was recorded as a medication as
early as 200 A.D. In about 500 A.D., the anti-diabetic activity of
Rhizoma Coptidis was noted; however, in most books the major
therapeutic activity of Rhizoma Coptidis is for the treatment of
infection and inﬂammation. In China, berberine is an over-the-
counter drug for the treatment of gastrointestinal infections, such
as bacterial diarrhea. The antidiabetic effect of berberine was
noted in 1988 in treating gastrointestinal infections patients with
diabetes in China. Berberine has been used as an anti-hypergly-
cemic agent by many physicians in China for many years, with
many clinical reports on the hypoglycemic action of berberine.
However, berberine has low bioavailability (o5%)3 due to poor
absorption. High dose oral administration usually causes gastro-
intestinal side effects, which greatly limit its clinical application.
In the following sections we will systemically review the
antidiabetic mechanism of action of berberine, its effect on
diabetic complications, and studies on its formulation. It is
hoped that these studies may contribute to the wider use of
berberine for the prevention of type 2 diabetes mellitus and its
complications.2. Antidiabetic effects and the mechanism of action
of berberine
Type 2 diabetes mellitus is a complicated metabolic disease
characterized by impairment of both glucose utilization and
gluconeogenesis. It has been reported that berberine has activity
comparable to sulphonureas and metformin in reducing bloodglucose in diabetic patients in China. Yin et al.4 reported that
administration of berberine (0.5 g, t.i.d.) at the beginning of each
major meal was able to reduce fasting blood glucose (FBG) in
adult patients with newly-diagnosed type 2 diabetes. HbA1c of
the patients was also decreased with berberine treatment, and is
comparable to that of metformin. In animal studies, berberine
treatment reduced weight gain, enhanced insulin sensitivity and
decreased blood glucose in both dietary and genetic animal
models of type 2 diabetes. Our study in rats with type 2 diabetes
induced by a high-fat diet and a low dose of streptozotocin
(STZ) showed that FBG was decreased and insulin tolerance was
improved signiﬁcantly by berberine5. Numerous investigations
on the antidiabetic mechanism of berberine have been under-
taken in the last several decades. The antidiabetic effect of
berberine was most often noted on skeletal muscle and adipose
tissue glucose uptake and liver gluconeogenesis6 (Fig. 1). It has
been shown that activation of AMP-activated protein kinase
(AMPK) plays an important role in these processes6–10.
2.1. Berberine activates AMPK
AMPK is an important energy-sensing protein in mammalian
cells. It acts as a fuel gauge by monitoring cellular energy levels,
such as AMP/ATP ratio. AMPK is thus an attractive drug target
that plays a key role in regulation of whole-body energy homeo-
stasis. Activation of AMPK in skeletal muscle and adipose tissue
leads to increased glucose uptake. Meanwhile, some studies
reported that activation of hepatic AMPK leads to increased
fatty acid oxidation and simultaneously inhibition of hepatic
glucose production as well as lipogenesis and cholesterol synthesis.
Recently, activation of AMPK was found to phosphorylate
transducer of regulated CREB protein 2 (TORC2), which
mediates cAMP response element binding protein (CREB)-depen-
dent transcription of peroxidome proliferator-activated receptor-g
coactivator-1 (PGC1) and its subsequent gluconeogenic targets
PEPCK (phosphoenolpyruvate carboxykinase) and G6Pase (glu-
cose-6-phosphatase), thus inhibiting hepatic gluconeogensis. It has
been consistently demonstrated that AMPK is a target for
berberine in the regulation of glucose metabolism. The most
recognized theory for the activation of AMPK by berberine is via
increasing AMP/ATP ratio by inhibiting ATP biosynthesis in
mitochondria. As early as 1985, berberine was shown to inhibit
NAD-linked respiration in isolated liver mitochondria. In 2003
this observation was conﬁrmed.
Berberine inhibited oxygen consumption and enhanced
glycolysis, thus increased AMP/ATP ratio. Berberine also
could dose-dependently inhibited respiration in L6 myotubes
and muscle mitochondria through a speciﬁc effect on respira-
tory complex I, rather than by the activity of either liver kinase
B1 (LKB1) or CAM kinase kinase (CAMKKb) which are the
upstream kinases responsible for the regulation of AMPK.
Based on these studies, it might be speculated that activation
of AMPK by berberine may contribute to regulation of
glucose and lipid metabolism via mitochondrial inhibition.
However, this possibility needs to be further studied.
2.2. Effect of berberine on glucose uptake
Skeletal muscle and adipose tissue are important target tissues
for insulin-stimulated glucose consumption. Many studies
have showed that berberine can increase glucose uptake in
Figure 1 Anti-diabetic effect of berberine: (1) Berberine inhibited mitochondrial function and activated AMPK to enhances glucose
uptake; (2) Berberine decreased the PEPCK and G6Pase gene expression to inhibit the gluconeogenesis; (3) Berberine decreased
adipogenesis through inhibition of PPARg and C/EBPa function; (4) Berberine might decrease intestinal glucose absorption by inhibition
of a-glucosidase.
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molecular mechanisms of insulin-dependent glucose uptake have
been broadly studied. The effect of berberine on glucose uptake
in skeletal muscle cells and adipose cells has been shown to be via
an insulin-independent way4,8–13. Several groups investigated the
effect of berberine on glucose transporters. Results are contro-
versial, with some labs ﬁnding that berberine could stimulate
glucose transporters (GLUT4/1) activity10,13, while others found
no stimulation of the GLUT4/19,11. On balance, only a weak
effect of berberine on the activity of glucose transporters appears
likely, which suggests that the regulation of GLUTs is not the
major mechanism by which berberine stimulates glucose meta-
bolism4. Berberine mimics insulin by increasing the glucose
uptake of 3T3-L1 adipocytes and L6 myocytes by inhibiting the
phosphatase activity of protein tyrosine phosphatase 1B (PTP1B)
and increasing the phosphorylation of IR, IRS1 and Akt. Their
results suggest that berberine represents a different class of anti-
hyperglycemic agents14. Berberine exhibited a synergistic effect on
insulin-induced glucose uptake and GLUT4 translocation in an
insulin-resistant state accompanied by enhancement of insulin-
induced PKCd and PKB activity. The key mechanism was related
to the inhibition of mTOR by berberine, which attenuated serine-
phosphorylation of IRS-1. It was suggested that berberine may
overcome insulin resistance by modulating key molecules in the
insulin signaling pathway, leading to increased glucose uptake in
insulin-resistant cells15. Further study on this aspect of berberine’s
actions needs to be conducted, and the direct targets of berberine
remain unknown. At the beginning of this year a study on
microRNA has been reported which suggests a new target of
berberine in glucose uptake16.
2.3. Effect of berberine on liver gluconeogenesis
Gluconeogenesis in the liver plays a key role in the pathogen-
esis of type 2 diabetes. Fasting blood glucose is determined byglucose production in liver and glucose deposition in periph-
eral tissues. In the insulin resistance state, enhanced glucose
output by liver contributes to hyperglycemia together with
reduced glucose uptake in skeletal muscle and adipose tissue.
Inhibition of hepatic glucose production is important for
glycemic control in diabetic patients. It has been clearly
reported that inhibition of transcription factors including
forkhead transcription factor O1 (FoxO1), hepatic nuclear
factor 4 (HNF4), and peroxisome proliferator-activated PGC-
1a are related to decreased expression of PEPCK and G6Pase,
two regulatory genes in gluconeogenesis. A recent paper
reported that berberine could suppress the transcription factor
FoxO1 and decrease the expression of key gluconeogenic
genes such as PEPCK and G6Pase. They measured the
expression of AMPK in the liver of a diabetic model and
speculated that berberine activated the expression of AMPK
and inhibited the liver gluconeogenesis17. Investigations from
our group further noted the effect of berberine on liver
gluconeogenesis in vivo and in vitro; we found that berberine
decreased gluconeogenesis by activation of AMPK. The
inhibitory effect of berberine on gluconeogenesis could be
diminished by the application of AMPK inhibitor compound
C. Our group also reported that the regulatory role of
berberine on glucocorticoid metabolism might be another
mechanism by which berberine acts on liver gluconeogenesis18.
2.4. Effect of berberine on adipogenesis
Adipose tissue is now recognized as a major endocrine organ,
releasing a wide range of protein factors including adipokines
and leptin, which regulate appetite and energy metabolism in
human and rodents19 through a variety of transcription factors
such as SREBP-1c, C/EBPa and PPARg. SREBP-1c accelerates
adipogenesis through the overexpression of adipogenic enzymes
such as tumor necrosis factor receptor superfamily member 6
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tase (ACS). These factors alone cannot promote differentiation
of non-adipogenic ﬁbroblasts, but when coexpressed in ﬁbro-
blasts expressing PPARg cell differentiation is enhanced. PPARg
appears to function as both a direct regulator of many fat-
speciﬁc genes and also as a ‘‘master’’ regulator that can trigger
the entire program of adipogenesis. In cells treated with
berberine, expression of several lipogenic genes including
PPARg, C/EBPa, SREBP-1c, fatty acid synthase, ACC, ACS,
lipoprotein lipase, aP2 and CD36 are suppressed20. Berberine
exerts an anti-adipogenic activity that is associated with the
down-regulation of C/EBPa and PPARg. This result suggests
that berberine-activated AMPK might play a role in its inhibi-
tory effect on the adipogenesis. Their data show that berberine
up-regulated the expression of two different sets of C/EBP
inhibitors, CHOP and DEC2, while down-regulating C/EBPa,
PPARg and other adipogenic markers and effectors in differ-
entiating 3T3-L1 preadipocytes and mature adipocytes. Further-
more, the anti-adipogenic activity of berberine was diminished
remarkably by adjusting the differentiation culture media and
also by knockdown of CHOP expression. Up-regulation of
C/EBP inhibitors appears to underlie the berberine-induced
repression of C/EBPa and PPARg and the inhibition of
adipogenesis21. Therefore, the inhibition of PPARg and C/EBPa
is likely the key mechanism for inhibition of adipogenesis by
berberine, which was closely related to the activation of AMPK
by berberine.
2.5. Effect of berberine on glucose absorption
It has been reported that carbohydrates need to be broken
down into smaller sugar molecules like glucose by a-glucosi-
dase in the small intestine. a-glucosidase inhibitors reduce the
postprandial peak in blood sugar and are useful for patients
with predominantly postprandial hyperglycemia because it
decreases glucose absorption by inhibition of a-glucosidase.
The Caco-2 cell model system has been used to evaluate the
bioactivity of a-glucosidase inhibitors. The Pan group
reported that a-glucosidase activity was inhibited by berberine
in the Caco-2 human enterocytic cell line. Further, they found
that berberine treatment could decrease glucose uptake at the
intestinal epithelium. These two mechanisms may be involved
in control of blood glucose by berberine22.
2.6. Effect of berberine on pancreatic b-cells
Type 2 diabetes mainly results from insulin resistance and b-cell
dysfunction. b-cell failure is responsible for progressive loss of
metabolic control in type 2 diabetic patients and the eventual need
for insulin treatment. Therefore, agents to protect b-cell function
might be a better choice for diabetic treatment. Berberine
treatment could promote pancreatic b cell regeneration and
functional recovery. Berberine reduced the fasting serum insulin
of diabetic rats and decreased the blood sugar by improving
insulin sensitivity of insulin receptors, rather than by stimulating
the pancreatic b cells to secrete insulin. This might reduce the
burden on the islet b-cells and play a protective role for islet b-
cells. However, interestingly, Ko et al.13 reported that berberine
can cause glucose-stimulated insulin secretion in Min6 islet b-cell
lines, and promote pancreatic b-cell proliferation, and activation
of cell regulatory proteins (ERK1/2), so that the insulin receptorsubstrate IRS-2 expression increases activation of the insulin/
insulin-like growth factor signaling cascades, which serve to reduce
blood sugar23,24.3. Role of berberine in treatment of diabetic complications
Type 2 diabetes is a chronic disease characterized by multiple
metabolic derangements. Patients with diabetes have a ten-
year shorter life expectancy. This is partly due to a number of
complications including cardiovascular disease, nephropathy
and retinopathy25, and thus a growing number of researchers
have focused on diabetes and its complications, with the aim
to expand our knowledge about pathogenic and pathophysio-




Endothelial dysfunction is a key event that links obesity,
diabetes, hypertension, and cardiovascular diseases. Endothe-
lial dysfunction has been known as an initiating, critical
factor, and main pathological change during the development
of diabetic vascular disease26, and it has been widely accepted
that diabetic vascular endothelial dysfunction is the base of
most of other diabetic complications such as diabetic cardio-
myopathy, diabetic retinopathy and nephropathy. Endothelial
dysfunction in diabetes reﬂects an imbalance between vasor-
elaxation and vasocontraction. A considerable body of evi-
dence implicates oxidative stress as a critical pathogenic
element in diabetic endothelial dysfunction27,28.
Our research group has demonstrated that berberine has
beneﬁcial effects on the treatment of type 2 diabetes and its
cardiovascular complications. Berberine treatment improved
glucose and lipid metabolism in type 2 diabetic rats induced by
high-fat diet combined with multiple low doses of streptozo-
tocin. The effect of berberine on lipid metabolism, at least
partly, contributed to the improvement of endothelial dys-
function. Meanwhile, berberine also signiﬁcantly protected
acetylcholine-mediated vasorelaxation in the aortas of diabetic
rats. This protective mechanism can be attributed to increased
NO bioavailability by up-regulating eNOS expression and
down-regulating expression of NADPH oxidase (NOX4)29. In
2012, the latest study from Cheng et al.30 in humans also
further supported our previous ﬁndings; they found that
berberine treatment ameliorated endothelial function by par-
tially reducing oxidative stress on the vascular endothelium
induced by circulating CD31þ/CD42 microphages in
humans. Their result demonstrated that increased ROS pro-
duction and Nox4 protein expression, and reduced NO
synthesis in human umbilical vein endothelial cells (HUVECs),
was reversed in the presence of berberine.
3.1.2. Diabetic cardiomyopathy
Cardiovascular complications are major causes of morbidity
and mortality in diabetic patients. Diabetic cardiomyopathy
(DCM) is the presence of myocardial dysfunction in the
absence of coronary artery disease and hypertension, which
was ﬁrst named by Rubler in 197231. Almost two of three
patients who present with symptomatic chronic heart disease
have abnormal glucose homeostasis. Hyperglycemia seems to
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triggers a series of maladaptive stimuli that result in increased
oxidative stress, interstitial ﬁbrosis, myocyte death, and dis-
turbances in ion transport and homeostasis. Presently, the
pathophysiology of diabetic cardiomyopathy is incompletely
understood and several mechanisms are under debate. Early
intervention to reverse metabolic toxicity is the most effective
method of prevention32. Currently,treatment of diabetic car-
diomyopathy does not differ from cardiomyopathy of other
etiologies, therefore, the principle of treatment has to follow
the appropriate guidelines, mainly including diuretics, ACE
inhibitors and b-blockers. These drugs also are the choice for
patients with diabetes, but the results of the intervention
studies for the prevention of diabetic complications have not
been satisﬁed.
Berberine as a new diabetic medicine has garnered increas-
ing attention. Although there is no evidence to prove the direct
efﬁciency of berberine in the diabetic cardiomyopathy, the
promising effects of berberine on endothelial dysfunction,
anti-oxidative stress, and the regulation of glucose and lipid
homeostasis have been demonstrated, all of which involve the
pathogenesis of diabetic cardiomyopathy. Berberine has been
reported as an effective anti-arrhythmic agent after ischemia-
reperfusion heart injury33. Wang et al.34 further reported that
berberine suppressed ischemic arrhythmias in a rat model of
diabetes mellitus, shortened the prolonged QTc, and reversed
the Kir2.1 to normal levels. All the evidence indicates that
berberine might be used to manage cardiac disease in diabetic
conditions, and suggest further clinical research.3.2. Diabetic nephropathy
Diabetic nephropathy is one of the most relevant diabetic
complications. In the last decade diabetic nephropathy has
become the main cause of end-stage renal disease (ESRD) in
the Western world35,36. In China, according to a cross-
sectional survey in 2012, the prevalence of chronic kidney
disease was 10.8%36. The pathological changes of diabetic
nephropathy include expansion of mesangial cells, accumula-
tion of extracellular matrix protein, thickening of glomerular
and tubular basement membranes, tubulointerstitial ﬁbrosis,
glomerulosclerosis and renal endothelial dysfunction asso-
ciated with albuminuria, proteinuria and reduction in glomer-
ular ﬁltration rate37–39. It has been accepted that optimal
control and maintenance of normal sugar level and blood
pressure are prerequisite to prevent the progression of diabetic
nephropathy. The combination of ACE inhibitors either with
calcium channel blockers or AT1 receptor blockers has been
suggested to be a promising therapeutic option to manage
patients with diabetic nephropathy.
Berberine as a novel antidiabetic agent has exhibited a
positive effect to treat diabetic nephropathy. Berberine
decreased the urinary albumin excretion (UAE) and improved
the pathological changes in diabetic rats. Oral administration
of berberine improved the ratio of kidney to body weight,
decreased the glomerular area, glomerular volume, fasting
blood glucose, blood urea nitrogen (BUN), blood creatinine
(Cr), and 24 h urinary protein in STZ-induced diabetic
nephropathy in rats40. Moreover, Lan’s study41 also showed
that berberine can activate the SphK-S1P signaling pathway
(which has been implicated in the pathogenesis of diabeticnephropathy) in alloxan-induced diabetic mice with nephro-
pathy. Furthermore, it has been shown that berberine could
prevent renal hypertrophy, TGF-b1 synthesis, ﬁbronectin
(FN) and Col IV accumulation. Hao et al.42 also shows that
berberine can improve the diabetic microvascular injury
in vitro and inhibit the formation of AGEs, suggesting
potential clinical therapies with berberine for diabetes and
its vascular complications. These result indicated berberine
might be an effective agents for diabetic nephropathy. How-
ever, the mechanisms of action of berberine on diabetic
nephropathy remains to be fully deﬁned.
3.3. Diabetic neuropathy
Diabetic neuropathy is the most common complication of
diabetes mellitus and up to 50% of patients with type 1 and
type 2 diabetes mellitus have neuropathy. Diabetic neuropathy
remains an unmet clinical problem and is poorly relieved by
conventional analgesics. Neuropathy is diagnosed when dia-
betic patients complain of symptoms and/or show signs of
peripheral nerve dysfunction after the exclusion of other
etiologies such as pain, paraesthesiae and loss of sensation43.
It has been shown that activation of polyol pathway plays a
key role in the pathogenesis of diabetic neuropathy.
Although many agents have been shown to be partially
effective, clinical studies have reported the difﬁculty of mana-
ging pain caused by these neuropathies44. Currently, multiple
strategies had been used to treat diabetic neuropathy, such as
multivitamins including B1, B2, B6, B12. Recently, aldose
reductase inhibitors, such as inositol have been applied to treat
diabetic neuropathy. However, there are very few drugs
available to directly treat diabetic neuropathy. Recent results
indicate that berberine could remarkably improve the nerve
conduction velocity45. Using berberine to treat diabetic neuro-
pathy in rats induced by STZ and in diabetic patients
demonstrated that berberine could signiﬁcantly improve the
median nerve, peroneal in nerve conduction velocity (NCV)46.
In 2010 and 2012, a study from Lu group reported that
berberine suppressed neuroinﬂammatory responses through
AMPK activation in BV-2 microglia and astrocytes, which
suggested a anti-neuroinﬂammatory effect of berberine47.
However, the mechanism of treatment of diabetic neuropathy
by berberine needs further study47,48.4. Modiﬁcation and formulations of berberine
Berberine has poor solubility and bioavailability, limiting its
application in the clinic. In recent years, researchers have used
various methods to improve the bioavailability of berberine.
Chemical modiﬁcation, dosage form transformation and drug
combinations are the most popular methods used.
4.1. Chemical modiﬁcation
Chemical modiﬁcation is a method that modiﬁes the structure
of the existing compounds by adding or removing chemical
groups. Through chemical modiﬁcation, drug properties can
be changed, including pharmacological activity, solubility, and
bioavailability.
Dai et al.49 used berberine as the original starting material and
hydrogenated it to yield tetrahydroberberine in the ﬁrst step of a
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to the N atom, producing a quaternary ammonium salt, which
was named CPU86017. This product has improved solubility
and oral bioavailability. CPU86017 was shown to protect from
malignant arrhythmias and sudden cardiac death by multiple
actions at ion channels because of its potent anti-arrhythmic
activity as a Class III anti-arrhythmic agent.
A derivative of berberine named dihydroberberine (dhBer)
was prepared and its effect on adiposity and glucose metabo-
lism was examined in a rodent model of type 2 diabetes fed a
high-fat diet. The results demonstrated that dhBer decreased
triglyceride accumulation in adipose tissue and improved
insulin resistance in this model. This improvement in in vivo
efﬁcacy is mainly due to the enhancement of oral bioavail-
ability: dhBer had a bioavailability of 2.65% compared to
berberine, which is not detectable in the plasma. However,
the bioavailability of dhBer is limited since it can be converted
back to berberine in the stomach, which hinders its
absorption.
8,8-Dimethyl-13,13a-dihydroberberine is a second newly
developed derivative of berberine. Addition of the two alkyl
groups was designed to block aromatization of dhBer by 8,8-
disubstitution. This new derivative, Di-Me has improved
aqueous solubility and acid stability, signiﬁcantly higher
bioavailability, and is not converted back to berberine
in vivo. Notably, it activates AMPK similarly to berberine
and dhBer50.
4.2. Dosage forms
Dosage form transformation is also a very important way to
improve the bioavailability of berberine. The aims are to avoid
ﬁrst pass elimination, increase the absorption and oral
bioavailability of berberine, reduce its side effects, as well as
increase patient compliance and tolerability.
4.2.1. Solid preparation
Tablets are the most common solid preparations. A large
number of new materials and new technologies have appeared.
Berberine has been prepared in many new forms on the basis
of these developments.
The solid dispersion of berberine was prepared and its
dissolution rate in vitro was studied. A fusion method with
PEG6000 as carrier and dissolvent-fusion method with PVP
K30 as carrier were used. The dissolved solution and the
in vitro dissolution were studied with the ultraviolet spectro-
photometric method detecting the concentration of berberine.
The results revealed that the solid dispersions with PEG6000
and PVP K30 as carriers improved the dissolution rate
signiﬁcantly, with complete dissolution in 15 min, demonstrat-
ing that the technology of solid dispersion can improve the
dissolution rate of berberine51. Zhang et al.52 developed a
duodenum-speciﬁc drug delivery system. They used hydro-
xypropyl methylcellulose acetate maleate (HPMCAM), a pH-
sensitive polymer, as a coating agent which dissolves at pH
3.6. HPMC-K4M and carbopol–934P were used as bioadhe-
sive materials. Within 24 h of fasting the pH value of gastric
juice is 1.3–1.8, rarely higher than 2.0. Acid entering into the
duodenum is neutralized by heavy carbonate to maintain a pH
of 6.0, nearly neutral. The gastric 24 h pH rhythm of duodenal
ulcer patients is similar to that of a normal subject, butduodenal pH value can be as low as 3.0–4.0. So when it is used
in duodenal ulcer patients, berberine coated in this tablet was
carried directly to duodenum without being released in the
stomach, and this made berberine release in the duodenum to
accumulate at the surface of the pathological ulcer. So the
function of a duodenum-speciﬁc eradiation therapy was
achieving for Hp.
4.2.2. Semi-solid preparation
Liu et al.53 prepared a suspension concentrate of berberine to
study and apply its antifeed activity to B. brassicae. First, they
screened a suitable moist dispersion making its HLB value
above 8 with the ﬂow point method. Then three preparations
of 20% berberine chloride suspension concentrate were pro-
duced. The result suggest that No. 3 SC of 20% berberine
hydrochloride had high bioactivity, with better touch-kill
activity and antifeed activity to B. brassicae, and higher
inhibition rate to Rhizoctonia DC and P. oryzae.
4.2.3. Particulate delivery system
Nano emulsion is a colloidal dispersed system with the
emulsion droplets sized 10 to 100 nm, dispersing in another
liquid. It consists of the kernel oil phase and surface-active
agent with a hydrocarbon chain. This nano-emulsion increases
the solubility of water insoluble drugs.
Sun et al.54 chose the suitable oil phase, surfactant and
cosurfactant to optimize the nano-emulsion drug delivery
system of berberine by studying the pseudo-ternary phase
diagram. The preparation method was optimized by entrap-
ment efﬁciency and drug loading as an evaluation standard.
Berberine nano-emulsion as a stable delivery system has a
good afﬁnity to the gastrointestinal lymphoid tissue, making
more of the drug absorbed by lymphatic pathways into the
blood, avoiding the liver, intestinal biological conversion and
absorption, and avoiding the hepatic ﬁrst-pass metabolism,
thereby improving the bioavailability of berberine. He et al.55
recast the traditional berberine by using the solid-self-micro-
emulsifying enteric bead as a new carrier. The self-micro-
emulsifying drug delivery system (SMEDDS) has great ability
to improve the oral bioavailability of berberine.
4.3. Complexation
4.3.1. Drug combination
Mo et al.56 produced a complex prescription metformin and
berberine (CPMB) to observe the inﬂuence on metabolism of
lipid in diabetic rats. CPMB (metformin:berberine¼60:130) was
administrated to diabetic rats which were induced by injection of
STZ for 3 months. Triglyceride (TG), total cholesterol (TC) and
low-density lipoprotein (LDL) were decreased signiﬁcantly after
treatment by CPMB (400 mg/kg), while high-density lipoprotein
(HDL) increased. The metabolism disorder of diabetic rats was
ameliorated by CPMB. Zhang et al.57 developed salvianolic acid
B-berberine double salt (SBS) to investigate its effects on diabetic
nephropathy in diabetic rats. Salvianolic acid B (Sal B) is one of
the water-soluble components from TCM-Salvia miltiorrhiza. It
has been shown that Sal B has multiple effects, including
improving renal function, alleviating ischemic damage, and an
antioxidative action. SBS is prepared by acid-base reaction. After
8 weeks of treatment with SBS the renal lesions of diabetic rats
were signiﬁcantly reduced.
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Battu et al.58 developed a complex of berberine with 2-
hydroxypropyl-b-cyclodextrin (HPbCD) after evaluating the
physicochemical characteristics of berberine. They used cyclo-
dextrins (CDs) to enhance berberine solubility. The phase-
solubility studies demonstrated that the aqueous solubility of
berberine improved almost 4.5-fold in the presence of 20%
HPbCD.
Our research group produced a complex of berberine and a
surfactant, sodium caprate, which also used as a intestinal
absorption enhancer, to improve the bioavailability of berber-
ine. The results showed that berberine can be absorbed at
various intestinal segments; sodium caprate signiﬁcantly
increased the absorption of berberine in intestine in vitro and
in vivo because of its inhibition of P-gp activity. Moreover,
both berberine and coadministration with sodium caprate
orally signiﬁcantly decreased fasting blood glucose and
improve glucose tolerance in diabetic rats. The hypoglycemic
effect of coadministration was remarkably stronger compared
with berberine alone59. Furthermore, our recent studies
demonstrate that sodium caprate augments the hypoglycemic
effect of berberine by activation of AMPK and inhibition of
hepatic gluconeogenesis.
As noted above, numerous methods were used to reform
berberine. The aim is to improve its bioavailability. The results of
the research cited above have made outstanding progress, but a
high-effect and low-toxicity form of berberine has yet to be
developed. This will be a future task for medical researchers.5. Conclusions
Berberine, a traditional anti-diarrheal drug, has promising
activity in the control of blood glucose and lipids in patients.
The mechanism of action has been suggested by recent studies.
Additionally, the role of berberine in treatment of diabetic
complications might be a new application of berberine. Based
on the existing literatures, the problems in exploring the
berberine as new antidiabetic drug include: (1) lack of a
multicenter, well controlled, long-term clinical trial to evaluate
the efﬁcacy of berberine; (2) lack of a clear mechanism of
action of berberine; (3) low bioavailability of berberine, and
lack of long-term and high-dose safety studies; (4), lack of
sufﬁcient formulation studies to improve dissolution, solubi-
lity, and bioavailability of berberine and its functional deri-
vatives. New formulations of berberine will be the next major
task for the research scientist. Berberine remains a promising
new drug in the treatment of diabetes and its complications.Acknowledgement
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